BCLI Brainstorm Cell Therapeutics Inc.
Healthcare$0.68-4.64%ClosedMarket Cap: $7.5M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.68
P/S
0.00
EV/EBITDA
-1.03
DCF Value
$-0.74
FCF Yield
-88.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
109.2%
ROA
-1676.0%
ROIC
91.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-2.0M | $-2.1M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-2.2M | $-2.4M | $— | — |
| FY null | $0.00 | NaN% | $-10.0M | $-10.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.0M | $-2.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.6M | $-2.9M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-3.1M | $-2.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-3.2M | $-3.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-11.7M | $11.6M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-3.0M | $-2.7M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-3.0M | $-2.5M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-2.5M | $-3.4M | $— | — |
| Q4 2023 | $343.0K | 80.8% | $-4.8M | $-5.6M | $-1.66 | — |